Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

US stocks rose on Friday, May 2, as the S&P 500, Dow Jones Industrial Average, and the tech-heavy Nasdaq all posted ...

Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will ...

Merck & Co has signed a deal with digital health ... amplitude and context whilst running in the background on an iOS or Android device. The app attracted a lot of attention during the pandemic ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

Merck's $11.5 billion deal to acquire Acceleron ... the six-minute walking test in PAH patients when added to stable background therapy, hitting its primary objectives. Moreover, the drug also ...

Mersana Therapeutics, Inc.’s MRSN share price has dipped by 8.13%, which has investors questioning if this is right time to ...

Nektar Therapeutics’s NKTR share price has dipped by 5.72%, which has investors questioning if this is right time to buy.

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when ...